Mannitol Bieffe

Mannitol, the active ingredient in Mannitol Bieffe, is an osmotic diuretic presented as a sterile solution for injection for intravenous use. It increases plasma osmolality, drawing water from tissues into the vascular compartment, thereby reducing intracranial and intraocular pressure and supporting renal diuresis in acute renal failure.

GNH USA supplies Mannitol Bieffe as a licensed, GDP‑compliant product sourced from the European Union, providing hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide with a reliable source of this essential osmotic agent.

Mannitol is used as an osmotic agent to manage conditions associated with elevated intracranial or intraocular pressure and to promote diuresis. - Intracranial hypertension: lowers intracranial pressure by drawing fluid from brain tissue into the bloodstream. - Glaucoma: reduces intraocular pressure, helping to prevent optic nerve damage. - Acute renal failure: enhances renal excretion of water and electrolytes, supporting urine output.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache reported during infusion. - Nausea or vomiting: gastrointestinal discomfort occurring shortly after administration. - Electrolyte imbalance: transient changes in sodium or potassium levels. - Fluid overload: signs of volume expansion such as peripheral edema. - Transient hypotension: brief drop in blood pressure during rapid infusion.

Serious or Rare Side Effects: - Acute renal failure: worsening kidney function in susceptible patients. - Pulmonary edema: accumulation of fluid in the lungs, especially with excessive dosing. - Severe electrolyte disturbances: hypernatremia or hypokalemia requiring intervention. - Anaphylactoid reaction: rare hypersensitivity with rash, bronchospasm, or shock.

When using Mannitol, clinicians should observe specific precautions to minimize risks and ensure optimal therapy. - Assess renal function: evaluate creatinine clearance before initiation. - Monitor fluid balance: track input/output and weight to avoid overload. - Check electrolytes: regularly measure serum sodium, potassium, and osmolality. - Use controlled infusion rate: administer slowly to reduce hypotension and pain. - Avoid in patients with severe pulmonary congestion: risk of worsening edema. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Loop diuretics: concurrent use may exacerbate electrolyte loss and dehydration. - Lithium: increased risk of lithium toxicity due to altered renal clearance.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect, monitor blood pressure. - Aminoglycoside antibiotics: potential for enhanced nephrotoxicity. - Insulin or oral hypoglycemics: osmotic shifts may affect glucose control. - Contrast media: combined osmotic load can increase risk of renal impairment.